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ABSTRACT
Objective: There is strong evidence that medication adherence and lifestyle changes are essen-
tial in patients undergoing secondary cardiovascular disease prevention. Cardiac rehabilitation
(CR) increases medication adherence and improves lifestyle changes. Patients with cardiac dis-
eases and a low educational level and patients with little social support are less responsive to
improve medication adherence and to adapt lifestyle changes. The aim of the present study
was to investigate the long-term effects of a socially differentiated CR intervention on medica-
tion adherence as well as changes in biological and lifestyle risk factors at two- five- and ten-
year follow-up.
Design: A prospective cohort study.
Setting: The cardiac ward at Aarhus University Hospital, Denmark.
Intervention: A socially differentiated CR intervention in addition to the standard CR program.
Subjects: Patients admitted with first-episode myocardial infarction between 2000 and 2004,
N¼ 379. Patients were defined as socially vulnerable or non-socially vulnerable according to
their educational level and extent of social network.
Main outcome measures: Primary outcome was medication adherence to antithrombotics,
beta-blockers, statins and angiotensin-converting enzyme inhibitors. Secondary outcomes were
biological and lifestyle risk factors defined as; total cholesterol, low-density lipoprotein choles-
terol, high-density lipoprotein cholesterol, glycated hemoglobin, blood pressure and smok-
ing status.
Results: No significant long-term effect of the intervention was found.
Conclusions: The results indicate a non-significant effect of the intervention. However, it was
found that equality in health was improved in the study population except concerning smoking.
General practitioners manage to support the long-term secondary cardiovascular disease preven-
tion in all patients regardless of social status.
KEY POINTS
 The socially differentiated intervention did not significantly improve medication adherence or
biological and lifestyle risk factors.
 Despite the non-significant effect of the intervention, equality in health was improved except
concerning smoking.
 General practitioners managed to support the long-term secondary cardiovascular disease
prevention in all patients regardless of social status.
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The ’2016 European Guidelines on cardiovascular dis-
ease prevention in clinical practice’ emphasizes that
medication adherence and lifestyle changes are
essential in secondary cardiovascular disease preven-
tion [1]. A core component of this is cardiac rehabilita-
tion (CR), which is a structured and multidisciplinary
intervention [2]. Several studies have shown that CR
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increases medication adherence and adherence to life-
style changes [3–8]. Long-term adherence to medica-
tion and lifestyle is crucial and associated with a lower
risk of mortality and recurrent events [1,2,9,10]. Key
strategies to improve adherence include a strong rela-
tionship between clinician and patient, a safe transi-
tion from hospital to primary care and communication
skills to ensure the patient’s understanding of the risks
of non-adherence [11].
Patients with a low educational level and little
social support are less responsive to achieving medica-
tion and lifestyle changes when diagnosed with car-
diovascular disease (CVD) [12–16]. Even in countries
with equal and free access to health care, social
inequalities are observed, implying that new initiatives
are needed in secondary cardiovascular disease pre-
vention [17].
In a Danish socially differentiated CR intervention
performed from 2000 to 2004, the focus was on mini-
mizing social inequality in patients diagnosed with
myocardial infarction (MI). At one-year follow-up,
socially vulnerable patients receiving the intervention
had a significantly better medication adherence, a sig-
nificantly better lipid profile and a significantly lower
systolic blood pressure (BP) when compared to socially
vulnerable patients receiving standard CR [18].
The aim of the present study was to investigate the
long-term effects of the above mentioned socially dif-
ferentiated CR intervention on medication adherence
as well as changes in biological and lifestyle risk fac-
tors at two- five- and ten-year follow-up.
Material and methods
Design and study participants
The study was designed as a prospective cohort study
and conducted from 1 April 2000 to 31 December
2004. The study population was enrolled at admission
to hospital and follow-up was conducted at two, five
and ten years. The patients entering the study were
all <70 years, admitted at Aarhus University Hospital,
Denmark and diagnosed with first episode of MI.
Patients were excluded if they suffered from severe
comorbidities such as stroke, dementia, mental disor-
ders (not depression or anxiety), retardation or severe
alcohol abuse [18,19].
The study was divided into two phases which con-
sisted of two years observation of clinical practice
regarding standard CR from 2000 to 2002 and fol-
lowed by a two-year intervention from 2002 to 2004.
A total of 508 patients were admitted with first epi-
sode MI and of these 379 patients (75%) who were
offered and attended CR were included in the study
and provided written informed consent [18,19].
When entering the study, patients were defined as
socially vulnerable or non-socially vulnerable. If
patients had a low educational level or lived alone
they were defined as socially vulnerable. 78 patients
admitted between 2000 and 2002 and 130 patients
admitted between 2002 and 2004 met the above cri-
teria and were categorized as socially vulnerable. The
remaining 171 patients, 55 patients admitted between
2000 and 2002 and 116 patients admitted between
2002 and 2004, were categorized as non-socially vul-
nerable. Further details of the definition have been
described previously [18,19].
Intervention
All 379 patients received standard CR in accordance
with international guidelines [1]. In CR phase I from
hospital admission to discharge, patients received
medical and acute surgical treatment. In CR phase II
from discharge and the next 12 weeks, patients had
three consultations with a doctor, four consultations
with a nurse, two consultations with a dietician and
participated in 12-week exercise program. In CR phase
III, patients were referred to general practice and
informed about relevant activities in The Danish Heart
Association and in the municipal sector [18,19].
The 130 patients categorized as socially vulnerable
and admitted between 2002 and 2004 received an
expanded CR intervention in addition to the standard
program. The expanded CR intervention was two
week longer in phase II and contained an extra con-
sultation with a nurse. The patients played an active
part in designing their own rehabilitation plan which
was sent to their general practitioner. The patients
were referred to a phase III start-up consultation in
general practice which was based on their individual
rehabilitation plan. The patients were referred to activ-
ities in The Danish Heart Association and the munici-
pal sector. Moreover, patients received a follow-up
telephone call from a nurse three months after com-
pleting phase II CR [18,19].
Outcomes
Primary outcome was medication adherence to antith-
rombotics, beta-blockers, statins and angiotensin-con-
verting enzyme inhibitors (ACE inhibitors). Secondary
outcomes were biological and lifestyle risk factors
defined as; total cholesterol, low-density lipoprotein
(LDL) cholesterol, high-density lipoprotein (HDL)
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cholesterol, glycated hemoglobin (HbA1c), blood pres-
sure and smoking status.
Data collection and measures
In Denmark, citizens are assigned a unique personal
10-digit number, which was used in the data collec-
tion. Information on medication adherence was
obtained from The Danish National Prescription
Register [20]. The database contains information on all
prescription drugs sold in Denmark. Medication adher-
ence was defined as the purchase of at least one pre-
scription every year of the follow-up period with the
specific ATC-codes B01AC04, B01AC06, B01AC56 for
anti-thrombotics, C07AA, C07AB for beta-blockers,
C10AA, C10AB, C10AC, C10AD, C10AX09, C10BA for
statins and C09AA, C09BB, C09CA, C09D for
ACE inhibitors.
Information on total cholesterol, LDL-cholesterol,
HDL-cholesterol, triglyceride and HbA1c was obtained
from a local laboratory database ’LABKA’ containing
information on results of all blood tests performed in
both the primary and secondary sector in the region
where Aarhus University Hospital is located [21].
Cholesterol and triglyceride were measured as mmol/L
and HbA1c was measured as mmol/mol. The value for
each of the laboratory outcomes at the time of follow-
up was an average value computed from all the val-
ues obtained in the follow-up period.
Information on blood pressure and smoking status
was collected through a questionnaire sent to the
patient’s general practitioner. In Denmark, patients
diagnosed with MI are entitled to an annual chronic
care consultation in general practice [22]. The general
practitioner was informed about the patient’s admis-
sion date and provided information on blood pressure
and smoking status at the annual consultation. Blood
pressure was measured as mm/Hg and smoking status
was reported as smoker/non-smoker. The question-
naire data were typed into a data documentation pro-
gram by two different evaluators. All answers were
assessed and if any dissimilarities occurred, the ques-
tionnaires were reevaluated by both evaluators.
Statistical analysis
The baseline characteristics of patients in each group
are described using frequencies and percentages or
means and standard deviations as appropriate.
Evaluations of the primary and secondary outcomes
were performed as visualizations of the outcome
measures during follow-up, and as statistical tests at
follow-up between socially vulnerable patients receiv-
ing the standard CR versus the expanded CR. To
evaluate the potential differences between the two
calendar periods, a supplemental analysis of the non-
socially vulnerable patients in the two corresponding
time periods was also conducted. All data were based
on yearly survivors in the study population. Data on
medication adherence were shown as yearly propor-
tions of patients who had redeemed at least one pre-
scription for each drug. The 95% confidence intervals
(CIs) of the proportions at follow-up were also calcu-
lated. Comparisons were evaluated using a chi-square
test of independence.
The biomarker data were based on all blood sam-
ples collected through LABKA and shown as medians
in visualizations and compared by calculating differen-
ces in means with 95% CIs and using a t test to test
for equality of means. The questionnaire data were
summarized and evaluated by calculating means and
proportions with the corresponding tests as described
for the medication and biomarker data. All data man-
agement and analyses were performed using Stata/MP
14.2, and p-values less than .05 were considered statis-
tically significant.
Results
Baseline characteristics of the study population can be
seen in Table 1. The mean age was 57 years and
approximately three out of four were male. As a result
of the definition of socially vulnerable patients had a
lower educational level and a higher fraction was liv-
ing alone. Total cholesterol, fasting blood glucose,
body mass index and smoking status were quite simi-
lar in all groups, except in the group of socially vulner-
able patients admitted between 2000 and 2002 who
had higher values and smoked more. Patients admit-
ted between 2000 and 2002 were prescribed ACE
inhibitors and statins less often than patients admitted
between 2002 and 2004 regardless of social status.
Medication adherence
As indicated in Figure 1, adherence to anti-throm-
botics during the ten-year follow-up was higher than
80%. This was also the case in relation to statins with
one exception, as the non-socially vulnerable patients
admitted between 2000 and 2002 showed a steady
above 60% adherence during the ten-year follow-up.
Adherence to beta-blockers was higher in the groups
admitted between 2000 and 2002 than in the groups
admitted between 2002 and 2004 irrespective of
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whether the patients were categorized as socially vul-
nerable or not. Adherence to ACE inhibitors was
around 40–60% in all groups throughout the 10-year
follow-up.
In relation to anti-thrombotics and ACE-inhibitors,
no significant differences in adherence were seen
between the socially vulnerable patients at two-, five-
and ten-year follow-up. In relation to beta-blockers, a
Figure 1. Proportions of patients redeeming at least one prescription for anti-thrombotics, beta-blockers, statins and ACE inhibi-
tors each year after first-episode myocardial infarction admission by groups of social vulnerability and calendar period of admis-
sion. Proportions are based on all patients with a first admission at Aarhus University Hospital, Denmark between 2000 and 2004
(N¼ 379) who survived each year of follow-up.
Table 1. Baseline characteristics of 379 patients admitted with first-episode myocardial infarction receiving socially differentiated
cardiac rehabilitation.







Standard Rehabilitation Expanded Rehabilitation Standard Rehabilitation Standard Rehabilitation
N¼ 78 N¼ 130 N¼ 55 N¼ 116
2000–2002 2002–2004 p Value 2000–2002 2002–2004 p Value
Age at admission, years 56 (8.2) 55 (8.5) .65 60 (7.6) 57 (73) .02
Gender, male 57 (73) 93 (71) .81 42 (76) 94 (81) .48
Education level (DUN) 3.2 (1.2) 3.3 (1.4) .66 4.8 (1.1) 4.8 (1.2) .79
Living alone 27 (35) 51 (39) .51 0 0 –
Total cholesterol, mmol/L 5.7 (1.5) 5.2 (1.0) .00 5.2 (0.9) 5.2 (0.9) .88
LDL cholesterol, mmol/L 3.5 (1.0) 3.2 (0.9) .02 3.3 (0.9) 3.2 (0.8) .58
HDL cholesterol, mmol/L 1.2 (0.3) 1.2 (0.3) .13 1.3 (0.3) 1.3 (0.4) .89
Triglyceride, mmol/L 2.0 (1.1) 1.7 (1.0) .02 1.5 (1.0) 1.7 (0.9) .25
Fasting blood glucose, mmol/L 7.5 (4.6) 6.9 (2.8) .25 6.8 (3.3) 6.7 (2.0) .69
Body Mass Index 27.3 (4.4) 26.3 (4.1) .10 26.4 (4.0) 26.5 (3.1) .77
Prescribed beta-blocker 71 (91) 116 (89) .67 49 (89) 107 (92) .50
Prescribed ACE-inhibitor 24 (31) 55 (42) .09 20 (36) 49 (42) .46
Prescribed statin 20 (26) 99 (76) .00 10 (18) 104 (90) .00
Prescribed anti-thrombotics 72 (92) 126 (97) .13 47 (86) 112 (97) .01
Current smoker 59 (76) 83 (64) .28 34 (62) 60 (52) .29
Patients are divided into groups based on social vulnerability and time period of admission.
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significant difference was seen at two- and five-year
follow-up (p-values .00 and .02), showing that signifi-
cantly more socially vulnerable patients receiving
standard CR redeemed at least one prescription on
beta-blockers in each of the follow-up years. No sig-
nificant difference was seen at ten-year follow-up. In
relation to statins, a significant difference was seen at
two-year follow-up (p-value .04). Significantly more
socially vulnerable patients receiving the expanded CR
purchased at least one prescription on statins in the
follow-up year. No significant differences were seen at
five- or ten-year follow-up (Table 2). As visualized in
Figure 1, some of the same tendencies were observed
in the group of non-socially vulnerable patients.
Biological and lifestyle risk factors
As seen in Figure 2, the levels of the blood tests were
acceptable. In general, the patients admitted between
2000 and 2002 had less acceptable blood test levels in
the first years after baseline regardless of being cate-
gorized as socially vulnerable or not. This effect was
less clear during the last part of the follow-up.
Socially vulnerable patients receiving the expanded
CR intervention had significantly lower total choles-
terol (p-values .00, .00), LDL cholesterol (p-values .00,
.00), triglyceride (p-values .00, .04) and HbA1c levels
(p-values .00, .01) at two- and five- year follow-up. No
significant differences were seen at ten-year follow-up.
Socially vulnerable patients receiving the expanded CR
Table 2. Assessment of medication adherence and biological and lifestyle risk factors among socially vul-
nerable patients admitted between 2000 and 2002 (N¼ 78) and between 2002 and 2004 (N¼ 130) at
Aarhus University Hospital, Denmark with first-episode myocardial infarction who participated in socially











Anti-thrombotic 2 0.90 78 0.95 128 1.1 (0.9–1.1) .37
5 0.92 75 0.89 125 1.0 (0.9–1.1) .46
10 0.94 66 0.90 107 1.0 (0.9–1.0) .33
Beta-blockers 2 0.82 78 0.55 128 0.7 (0.6–0.8) .00
5 0.68 75 0.52 125 0.8 (0.6–1.0) .02
10 0.58 66 0.47 107 0.8 (0.6–1.1) .16
Statins 2 0.82 78 0.91 128 1.1 (1.0–1.3) .04
5 0.88 75 0.86 125 1.0 (0.9–1.1) .74
10 0.91 66 0.90 107 1.0 (0.9–1.1) .79
ACE inhibitors 2 0.38 78 0.47 128 1.2 (0.9–1.7) .23
5 0.44 75 0.53 125 1.2 (0.9–1.6) .22
10 0.50 66 0.56 107 1.1 (0.8–1.5) .43
Total Cholesterol 2 5.1 78 4.4 130 0.6 (–0.8 to 0.4) .00
5 4.7 74 4.3 116 0.4 (–0.6 to 0.2) .00
10 4.3 68 4.2 105 0.1 (–0.3–0.2) .51
HDL Cholesterol 2 1.2 78 1.3 130 0.1 (0.1 0.2) .01
5 1.3 74 1.3 114 0.0 (0.1–0.1) .95
10 1.2 68 1.3 103 0.1 (0.0–0.2) .11
LDL Cholesterol 2 3.0 77 2.5 130 0.5 (0.7 to 0.4) .00
5 2.6 74 2.3 111 0.3 (0.4 to 0.1) .00
10 2.4 68 2.3 102 0.1 (0.3–0.1) .37
Triglyceride 2 2.0 78 1.5 130 0.4 (0.7 to 0.2) .00
5 1.8 74 1.6 112 0.2 (0.4 to 0.0) .04
10 1.7 68 1.6 103 0.03 (0.3–0.2) .80
HbA1c 2 50.7 30 42.3 117 8.4 (12.6 to 4.2) .00
5 52.1 40 45.7 71 6.4 (11.3 to 1.4) .01
10 48.9 43 44.9 93 4.0 (8.1–0.1) .06
Systolic blood pressure 2 131.8 53 131.4 93 0.4 (6.0–5.1) .89
5 132.7 54 132.6 96 0.1 (6.8–6.5) .97
10 134.1 55 132.4 92 1.7 (7.5–4.2) .57
Diastolic blood pressure 2 79.5 53 79.0 93 0.5 (3.9–2.9) .77
5 78.3 54 79.0 96 0.7 (2.7–4.1) .68
10 80.0 55 79.4 92 0.5 (4.2–3.2) .78
Smoking status 2 0.52 33 0.46 70 0.9 (0.6–1.4) .58
5 0.59 39 0.47 68 0.8 (0.6–1.2) .23
10 0.37 43 0.37 75 1.0 (0.6–1.6) .98
Values are based on yearly survivors and on available data from registers and questionnaires.
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intervention showed significantly higher HDL choles-
terol at two-year follow-up (p-value .01). No significant
differences were seen at five- and ten-year follow-up
(Table 2). As visualized in Figure 2, some of the same
tendencies were present in the group of non-socially
vulnerable patients. However, no significant differen-
ces were seen in relation to triglyceride.
Of the 379 forwarded questionnaires, 301 were
returned by the general practitioners (response rate
79%). Not all returned questionnaires were filled out
completely. The response rate in the group of socially
vulnerable patients admitted between 2000 and 2002
was 77% and it was 81% in the group of socially
vulnerable patients admitted between 2002 and 2004
(p-value .50). The response rate in the group of non-
socially vulnerable patients admitted between 2000
and 2002 was 69% and it was 84% in the group of
non-socially vulnerable patients admitted between
2002 and 2004 (p-value .02).
As seen in Figure 3, patients had acceptable mean
blood pressure levels regardless of being categorized
as socially vulnerable or not. No mean blood pressure
levels of more than 135/85mm/Hg were seen. No sig-
nificant differences in systolic or diastolic blood pres-
sure were seen between socially vulnerable patients
receiving the standard CR and socially vulnerable
patients receiving the expanded CR during the ten-
year follow-up (Table 2). As visualized in Figure 3,
some of the same tendencies were seen in the group
of non-socially vulnerable patients.
Figure 3 shows that a higher proportion of socially
vulnerable patients than non-vulnerable patients
smoked . The proportion of smokersdecreased during
the first two years after admission in all groups when
compared to baseline data (Table 1). The proportion
of smokers increased from two to five years after
admission and declined again in each of the groups
during the remaining part of the ten-year follow-up.
No significant differences in smoking status were seen
between socially vulnerable patients receiving the
standard CR and socially vulnerable patients receiving
the expanded CR during the ten-year follow-up (Table
2). As visualized in Figure 3, the same tendency was
present in the group of non-socially vulner-
able patients.
Discussion
The present study investigated the long-term effects
of a socially differentiated CR intervention on
Figure 2. Median values of blood test results among patients each year after first-episode myocardial infarction by groups of
social vulnerability and calendar period of admission. Medians are based on data from all patients with a first admission at
Aarhus University Hospital, Denmark between 2000 and 2004 (N¼ 379) who have a valid register-based value of each type of
blood test within each year of follow-up.
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medication adherence, biological and lifestyle risk fac-
tors at two- five- and ten-year follow-up. Overall, no
significant long-term effects were found. However, sig-
nificantly more patients categorized as socially vulner-
able receiving the expanded CR redeemed at least
one prescription on statins at the two-year follow-up.
Also, socially vulnerable patients receiving the
expanded CR had significantly lower levels of total
cholesterol, LDL cholesterol, triglyceride and HbA1c at
two- and five-year follow-up and a significantly higher
level of HDL cholesterol at two-year follow-up.
Strengths and weaknesses
A strength of the study is that the majority of the
data are retrieved from Danish registers, which can be
assumed to provide an almost complete follow-up.
The risk of selection bias in data collected through
questionnaires should, however, always be considered.
As the questionnaires were filled out by the patients’
general practitioners we have no reasons to believe
that selection bias was present. Also, no significant dif-
ferences were seen in the response rate between the
socially vulnerable patients receiving either the stand-
ard or expanded CR.
The ten-year follow-up period is a major strength.
To our knowledge, no previous studies have investi-
gated the ten-year effect of a socially differentiated CR
intervention. However, it must be considered that the
effect of the intervention perhaps was watered down
over the years and that other non-measurable com-
peting reasons could have influenced the long-
term effect.
Another strength is that even though we do not
show any convincing effect of the intervention, we do
show that it is possible to tailor a long-term secondary
cardiovascular disease prevention which improves
equality in health. In Denmark, the general practitioner
is the main care provider in long-term secondary car-
diovascular disease prevention. Our results show that
general practitioners manage to successfully support
the socially vulnerable patients except when it comes
to smoking. However, the proportion of smokers
increased from two to five years after after admission
regardless of social status indicating that some life-
style changes are more difficult to maintain in the
long-term secondary prevention.
A weakness of the study is the external validity. It
can be difficult to apply the results to countries with-
out free access to health care and countries which do
Figure 3. Mean values and proportions of blood pressure and smoking status among patients with first-episode myocardial infarc-
tion admission by groups of social vulnerability and calendar period of admission. Values are based on questionnaire data from
general practitioners of all patients with a first admission at Aarhus University Hospital, Denmark between 2000 and 2004
(N¼ 379) with a valid questionnaire response at each time of follow-up.
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not offer reimbursement of medicine costs. However,
all CR programs offered in Europe to patients suffering
from CVD must be expected to comply with the
recommendations by ’The European Society of
Cardiology’ [1].
It is also a weakness that data are based on yearly
survivors if there was any selection bias in the deaths.
However, it has earlier been established that no sig-
nificant differences in all-cause mortality were seen at
ten-year follow-up between the socially vulnerable
patients receiving the standard CR and the socially
vulnerable patients receiving the expanded CR [19].
Moreover, it is a weakness if the socially vulnerable
patients included in the study are different than the
socially vulnerable patients who were not referred to
or did not participate in CR. If the socially vulnerable
patients who participated were the ones with most
ressources and the most healthy, there is a risk of
selection bias and type-2-errors.
In addition, it seems that time plays a part in the
results. One could suspect that beta-blockers were
more frequently used between 2000 and 2002 and
that statins were more frequently used between 2002
and 2004. Also, it seems that the development in the
blood test levels could be a sign that the threshold
values have been lowered over the years. Reflections
concerning the non-parallel time periods in this study
and the non-randomized study design have been dis-
cussed in detail elsewhere [19].
Findings in relation to other studies
In an Italian randomized controlled trial from 2012 by
Sturchio et al., the aim was to evaluate the effective-
ness of an individualized management program to
modify the risk profile in patients with coronary artery
disease [8]. At nine-month follow-up a significant dif-
ference was seen between patients randomized to the
intervention and patients randomized to standard care
in relation to total – and LDL cholesterol, triglyceride,
systolic blood pressure, number of smokers and adher-
ence to beta-blockers, ACE inhibitors and statins. The
intervention by Sturchio et al. [8] was significantly
more effective than standard care. This could indicate
that the intervention offered was more effective than
the socially differentiated intervention in the present
study. However, it must be emphasized that the fol-
low-up time in the study by Sturchio et al. [8] was
short. Also, there is no information in the study about
the patients’ social status. If only non-socially vulner-
able patients participated it could cause selection bias
and thus reduce the validity of the study. Moreover, it
must be considered that the reason why we do not
see any significant differences is that standard CR
(’usual care’) in Denmark has such a high quality that
it may be difficult to detect any differences between a
standard and an expanded intervention.
In a British systematic review and qualitative syn-
thesis from 2014 by Rashid et al. [11], the aim was to
understand the factors that promote medication per-
sistence seen from a patient perspective. It was found
that the support of family members is important,
which goes well in line with the definition in this
study of being socially vulnerable with little social sup-
port or not. Moreover, it was found that a good rela-
tionship between the patient and the prescribing
clinician is very important, which in Denmark almost
always will be the general practitioner. This supports
our previous statement that general practitioners
seemingly manage to support the socially vulnerable
patients so well that equality in medication adherence
and biological and lifestyle risk factors were improved.
Furthermore, it was stated by Rashid et al. [11] that
patients believe that medicine is more powerful than
life-style changes. This is applicable to the results in
the present study concerning smoking.
Conclusion and implications
The present study did not find any significant long-
term effects of the socially differentiated CR interven-
tion. Overall, it was found that patients regardless of
being categorized as socially vulnerable or not were
adherent to prescribed medicine and that their bio-
logical and lifestyle risk factors were acceptable at
follow-up. The authors acknowledge the general
practitioners’ effort in supporting the patients in the
long-term secondary prevention and equality in health
was improved in the socially vulnerable part of the
study population compared to existing literature
where socially vulnerable patients to a lesser extent
achieve medication adherence and life style changes
[12–17]. A major challenge is how to reduce the pro-
portion of smokers in the long-term secondary pre-
vention. where equality in health was not improved.
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